---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-023114"
form_type: "8-K"
ticker: "VTGN"
cik: "0001411685"
company_name: "Vistagen Therapeutics, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T17:03:51.210863+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Vistagen reports positive Phase 3 PALISADE-2 fasedienol results for SAD; Q1 net loss $6.9M

## Summary
- Phase 3 PALISADE-2: fasedienol met primary endpoint (SUDS LS mean diff -5.8, p=0.015) and secondary CGI-I responder rate (37.7% vs 21.4%, p=0.033).
- Net loss for Q1 FY2024 was $6.9M, down from $19.8M YoY; R&D expense decreased $11.1M to $4.2M.
- Cash $9.6M at June 30, 2023; raised ~$16.9M from shares in July/Aug 2023, with additional $15.2M expected by Aug 14.
- Itruvone (PH10) moving to Phase 2B for MDD after successful US Phase 1; PH80 Phase 2A showed significant hot flash reduction (p<.001).
- Planning Phase 3 PALISADE-3 and FEARLESS in 2024; fasedienol well-tolerated with no serious AEs.

## SEC filing metadata
- accession: 0001437749-23-023114
- form_type: 8-K
- ticker: VTGN
- cik: 0001411685
- company_name: Vistagen Therapeutics, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411685/000143774923023114/0001437749-23-023114-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411685/000143774923023114/vtgn20230810_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-023114
- JSON: https://secwatch.observer/filing/0001437749-23-023114.json
- Plain text: https://secwatch.observer/filing/0001437749-23-023114.txt

## Key facts
- Earnings Releases
  Vistagen Therapeutics, Inc. reported financial results for fiscal year 2024 first quarter ended June 30, 2023.
  - Period: fiscal year 2024 first quarter ended June 30, 2023
  - Result: reported results
  source text: On August 10, 2023, Vistagen Therapeutics, Inc. (the “ Company ”) issued a press release to announce the Company’s financial results for its fiscal year 2024 first quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1411685/000143774923023114/0001437749-23-023114-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.